OOIR: Observatory of International Research

Papers

(The H4-Index of npj Parkinsons Disease is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease	254
Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced Parkinsonism	152
Investigating the ageing-Parkinson’s disease nexus: standardisation of in vitro models and techniques by the PD-AGE network	147
Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease	145
Classification of Parkinson’s disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome	132
Longitudinal non-negative matrix factorization identifies the altered trajectory of motor symptoms in Parkinson’s disease	113
Corneal confocal microscopy differentiates patients with secondary parkinsonism from idiopathic Parkinson’s disease	113
Transformer-based long-term predictor of subthalamic beta activity in Parkinson’s disease	110
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology	109
Push-pull effects of basal ganglia network in Parkinson’s disease inferred by functional MRI	102
Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease	102
Proinflammatory and GABA eating bacteria in Parkinson's disease gut microbiome from a meta-analysis perspective	100
VisionMD: an open-source tool for video-based analysis of motor function in movement disorders	91
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances	88
Cdk5 phosphorylation-induced SIRT2 nuclear translocation promotes the death of dopaminergic neurons in Parkinson’s disease	86
Differential memory enrichment of cytotoxic CD4 T cells in Parkinson’s disease patients reactive to α-synuclein	86
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease	78
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease	76
Differences in brain aging between sexes in Parkinson’s disease	72
Genetic risk and plasma biomarkers of dementia with Lewy bodies in a Chinese population	72
Alpha synuclein modulates mitochondrial Ca2+ uptake from ER during cell stimulation and under stress conditions	72
Phase II pilot randomized trial of zonisamide for disease modification in prodromal Lewy body disease	71
Advanced brain aging in Parkinson’s disease with cognitive impairment	70
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies	69
Association between functional gastrointestinal disorders and Parkinson’s disease in a prospective cohort study	68

Targeting the hypothalamic a11 nucleus to treat parkinsonian-like nociceptive impairments	67
Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research	66
Direct disassembly of α-syn preformed fibrils into α-syn monomers by an all-D-peptide	66
Patterns of cerebellar cortex hypermetabolism on motor and cognitive functions in PD	64
The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson’s disease mouse model	64
A systematic exploration of unexploited genes for oxidative stress in Parkinson’s disease	64
The experience of Anxiety for people with Parkinson’s disease	64
EGFR phosphorylates DNAJB1 to suppress α-synuclein aggregation in Parkinson’s disease	63
Redefining the hypotheses driving Parkinson’s diseases research	62
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson’s disease	61
Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset	60
Unveiling early signs of Parkinson’s disease via a longitudinal analysis of celebrity speech recordings	60
Baseline [18F]FP-CIT PET-based deep learning prediction of levodopa-induced dyskinesia in Parkinson’s disease	59
Functional network differences between unilateral and bilateral deep brain stimulation of the subthalamic nucleus	57
Inhibition of T cell infiltration and soluble TNF signaling is neuroprotective in the alpha-synuclein overexpressing mouse model of Parkinson’s disease	57
Characterization of the pathogenic α-Synuclein Variant V15A in Parkinson´s disease	56
Reply to Matters Arising: Is congenital anosmia protective for Parkinson’s disease triggered by pathogenic entrance through the nose?	54
In memorium, Michael Zigmond, PhD	54
Cortical macro- and microstructural changes in isolated rapid eye movement sleep behavior disorder	53
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease	52
Identification of PLOD3 and LRRN3 as potential biomarkers for Parkinson’s disease based on integrative analysis	51
A skin-specific α-Synuclein seeding amplification assay for diagnosing Parkinson’s disease	51
Synuclein phosphorylation: pathogenic or physiologic?	49
Mapping the developmental path for Parkinson’s disease therapeutics	48